Early studies found that ‘sufficient’ T cell infiltration in tumor sites is critical for the response to anti-PD-L1 therapy, and that poor representation of CD8+ T cells in tumors is a fundamental hurdle to successful immunotherapy (20, 58). This evidence concerns the gene CD8A and neoplasm.